News & Events

GeneCentric to Present Data on the Purity Independent Subtyping of Tumor (PurIST) Test at AACR Pancreatic Conference

Durham, NC, September 13, 2022 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurISTSM, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer […]

GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 or […]

GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study

New HR-NMIBC molecular analyses to be presented at the 2022 AUA Annual Meeting Durham, NC, May 10, 2022 –  GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American […]

Neil Hayes, GeneCentric co-founder, highlighted for his work and upcoming AACR presentation by UTHSC where he is the Director of the Center for Cancer Research.

For two decades, scientists have been able to identify the molecular signature of specific cancers by isolating the RNA, responsible for dictating which proteins are produced and, by extension, how the cells behave in the body. Now, Neil Hayes, MD, MS, MPH, director of the Center for Cancer Research at the University of Tennessee Health […]

GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients with Head and Neck Cancer

New molecular analyses to be presented at the AACR Annual Meeting 2022 DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the upcoming oral presentation of the discovery and initial clinical utility of a novel signature that identifies patients with head and neck squamous cell carcinoma (HNSCC) […]

GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer

The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine […]

WRAL TechWire Interview with GeneCentric CEO About Recent Company Accomplishments

GeneCentric CEO Michael Milburn discusses recent company accomplishments and the year ahead, as well as and current trends in biotech and pharma with WRAL TechWire. Read More

GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing

Proceeds to expand and commercialize growing pipeline of RNA-based molecular diagnostics Durham, N.C., Nov. 8, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the […]

Collaboration with Labcorp recently featured in the Triangle Business Journal

Our new collaboration with Labcorp to develop and commercialize RNA-based oncology diagnostics was recently featured in the Triangle Business Journal. Read more at https://bizj.us/1qcgmk.

GeneCentric Therapeutics Collaborates with Labcorp to Develop Novel RNA-Based Oncology Diagnostics

DURHAM, N.C. – October 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer. This latest collaboration builds on the organizations’ existing […]

GeneCentric Therapeutics Announces Presentations at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting

Ongoing Collaboration with Basilea Pharmaceutica International Ltd and their Lisavanbulin Clinical Program in Glioblastoma Will Be Highlighted at ASCO DURHAM, NC / ACCESSWIRE / June 2, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually […]

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 9, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung […]

GeneCentric Therapeutics Announces the Appointment of Philippe Chemla, PhD, MBA, as Chief Business Officer

Durham, NC, February 3, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise, announced today the appointment of Philippe Chemla, PhD, MBA,  as Chief Business Officer.  Dr. Chemla has extensive experience across multiple areas of life sciences research and development, with a focus on strategic collaborations and business development. “Philippe brings a strong […]

GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

RNA-based investigation builds on prior bladder cancer research Durham, NC, August 12, 2020 – GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform […]

GeneCentric Therapeutics and Erasmus University Medical Center Enter Bladder Cancer Research Collaboration

Research to focus on potential biomarkers of disease progression, immune and treatment response in the setting of Non-Muscle Invasive Bladder Cancer DURHAM, N.C., USA and ROTTERDAM, THE NETHERLANDS, August 5, 2020 — GeneCentric Therapeutics, Inc. and Erasmus University Medical Center (EUMC) today announced that they have entered into a research collaboration to identify RNA-based drug […]

GeneCentric Announces “Advances in RNA-based Biomarker Development for Precision Oncology” Webinar Series

This three-part webinar series, “Advances in RNA-based Biomarker Development for Precision Oncology”, will highlight trends in RNA-based biomarker development for precision oncology, ranging from the use of gene expression signatures in the development cancer therapies, to the development of RNA-based companion diagnostics, to novel applications for RNA-based biomarkers in cancer treatment. Part 1 is August 24th, with Parts 2 and 3 September 10th and October 8th.

Pancreatic Cancer Action Network and GeneCentric Therapeutics Launch Partnership in Pancreatic Cancer Research

Collaboration will focus on applying advanced RNA-based molecular technologies to predict disease progression and identify potential drug response biomarkers MANHATTAN BEACH, CA and DURHAM, N.C., July 29, 2020 — The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. today announced that they have entered into a collaborative research partnership for the advancement of RNA-based […]

GeneCentric has moved its offices

GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713

Covid-19 Status

GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along with specific guidance for travelers. Currently, the company doesn’t anticipate any changes with its current client projects and will continuously update clients.

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.  The data are derived from GeneCentric’s expertise in the identification of RNA-based Predictive […]